Evidence map›Paper›PMID 31217906›Full record

ArticleOncotarget2019

Dissecting the role of RNA modification regulatory proteins in melanoma.

Parmanand Malvi, Biao Wang, Shreni Shah, Romi Gupta

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Targeting the 3D genome by anthracyclines for chemotherapeutic effects.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. METTLing in Stem Cell and Cancer Biology.Stem cell reviews and reports · 2023
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Parmanand MalviDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Biao WangDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Shreni ShahDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Romi GuptaDepartment of Pathology, Yale University School of Medicine, New Haven, CT, 06510, USA.
Yale University · US

Funding

A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMAR01CA200919 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2016 to 2020
$1.8M
Nucleoporin NUP205-driven Novel Pathway in Melanoma Tumor Growth and MetastasisR01CA196566 · NCI · YALE UNIVERSITY · PI WAJAPEYEE, NARENDRA · 2016 to 2020
$1.8M
PERSONALIZED THERAPY FOR p16-DEFICIENT MELANOMAR03CA221926 · NCI · YALE UNIVERSITY · PI GUPTA, ROMI · 2018 to 2019
$158k
NCI NIH HHS R01 CA196566NCI NIH HHS R01 CA200919NCI NIH HHS R03 CA221926
6 · The paper itself

Abstract

Melanoma is the deadliest form of skin cancer. Despite recent advances in medicine and the development of new treatments for melanoma, cures remain elusive as acquired resistance to both targeted and immunotherapies are becoming common. Therefore, more studies are conducted to dissect underlying molecular mechanisms that drive melanoma growth in order to provide better therapeutic option. Here, employing a comprehensive and unbiased analysis of different RNA modification regulatory proteins using various publicly available databases we identify the most relevant RNA modifying proteins that plays crucial role in melanoma development. Our study started with the analysis of various genetic alterations (amplifications, mutations/deletion) as well as RNA overexpression of these RNA modification regulatory proteins in The Cancer Genome Atlas melanoma database. We then analyzed their expression in The Human Protein Atlas data. The result of analysis revealed that only a subset of RNA modification regulatory proteins are overexpressed in >75% of melanoma patient cases as compared to normal skin. However, when examined in Oncomine dataset we found only two genes (METTL4 and DNMT3A) were significantly overexpressed in melanoma samples versus normal skin samples and matched with the results of The Human Protein Atlas data. Therefore, we functionally validated METTL4 and DNMT3A using shRNA-mediated knockdown and found that their knockdown in melanoma cells led to melanoma cells growth inhibition. Collectively, in this study, we investigated the epitranscriptomic landscape of melanoma using various publicly available database and identified DNMT3A and METTL4 as the most relevant potential regulators of melanoma growth.

Indexed as

BRAF mutant melanomaepitranscriptomeMAPKmelanomaRNA modifications

Identifiers

PMID31217906
PMCPMC6557201
OpenAlexW2955282851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.